Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide with EGFR-TKI in Advanced EGFR-TKI-resistant NSCLC
NCT02815007Phase 2Unknown
- Start
- Jun 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in non-small cell lung cancer (NSCLC). Primary endpoints: Objective Remission Rate at 15 months and Disease Control Rate at 15 months. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02815007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815007.